MODULATION OF POSTPRANDIAL LIPEMIA, INFLAMMATION, AND VASCULAR FUNCTION BY PCSK9 INHIBITION IN DIABETES. - PLEIADES-pcsk9

Franciscus Gasthui0 个研究点开始时间: 2017年1月3日最近更新: 2017年5月22日

适应症

试验速览

暂无简介。

•- Age of 18 years or older
•- Fasting triglycerides levels between 1.8 mmol/L and 7.0 mmol/L
•- Diabetes mellitus type 2 on intensive insulin treatment (three times short acting and one daily long acting) (unchanges for >10 weeks prior to consent)
•- Stable glucose regulation last 6 months (HbA1c >6.5% - < <9.0%)
•- Stable lipid lowering therapy last 2 months (no changes in regiments or dose)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Current smoking
•- Impaired renalfunction (MDRD <60 ml/min/1.73 m2)
•- Recent cardiovascular event (<6 months) (myocardial infarction, coronary artery bypass grafting, stroke)
•- Severe hyperglycemic events in the past 6 months (hyperglycemia >20 mmol/L requiring hospital admittance)
•- Recent or current use of pcsk9 antibodies

发起方

Franciscus Gasthui